Organigram Global (OGI)
NASDAQ:OGI
OGI Stock Chart & Stats
$1.40
-$0.09(-5.33%)
At close: 4:00 PM EST
$1.40
-$0.09(-5.33%)
Day’s Range― - ―
52-Week Range$1.00 - $2.24
Previous CloseN/A
Volume319.88K
Average Volume (3M)503.24K
Market Cap
$190.29M
Enterprise Value$264.69M
Total Cash (Recent Filing)$8.38M
Total Debt (Recent Filing)$8.45M
Price to Earnings (P/E)3.9
Beta1.45
Next Earnings
Apr 14, 2026EPS Estimate
>-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.10
Shares Outstanding136,337,340
10 Day Avg. Volume445,302
30 Day Avg. Volume503,243
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)1.03
Price to Sales (P/S)1.39
P/FCF Ratio-14.61
Enterprise Value/Market Cap1.39
Enterprise Value/Revenue0.95
Enterprise Value/Gross Profit13.92
Enterprise Value/Ebitda-16.99
Forecast
1Y Price Target
$2.66Price Target Upside90.00% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering4
EPS Forecast (FY)0.11
Revenue Forecast (FY)$229.76M
Bulls Say, Bears Say
Bulls Say
Acquisition And European ExpansionAnalyst considers the acquisition strategically significant as it positions Organigram in Germany and creates a platform to expand across European markets, supporting potential revenue growth.
Higher-margin Product SalesAnalyst notes the deal enables Organigram to sell higher-margin flower into European markets, which could improve overall profitability as international sales scale.
Operational Strength And DistributionAnalyst points to Sanity Group's improving gross margins and positive operating profitability, together with the Motif acquisition's added sales channels, as elements that can strengthen margins and accelerate top-line growth.
Bears Say
Balance Sheet Impact And Shareholder DilutionAnalyst warns the transaction requires cash and issuance of Organigram shares, which could weaken the balance sheet and alter shareholder structure through dilution.
Operational Disruption And Product Quality RiskAnalyst highlights operational disruptions and product quality issues that constrained international shipments and increased competitive pressure in certain categories, posing execution risk.
Revenue And Earnings ShortfallAnalyst reports net revenue missed expectations because international sales were weaker and domestic adult-use demand softened, resulting in adjusted operating earnings falling short of forecasts.
Organigram Global News
OGI FAQ
What was Organigram Global’s price range in the past 12 months?
Organigram Global lowest stock price was $1.00 and its highest was $2.24 in the past 12 months.
What is Organigram Global’s market cap?
Organigram Global’s market cap is $190.29M.
When is Organigram Global’s upcoming earnings report date?
Organigram Global’s upcoming earnings report date is Apr 14, 2026 which is tomorrow.
How were Organigram Global’s earnings last quarter?
Organigram Global released its earnings results on Feb 10, 2026. The company reported $0.103 earnings per share for the quarter, beating the consensus estimate of -$0.007 by $0.11.
Is Organigram Global overvalued?
According to Wall Street analysts Organigram Global’s price is currently Undervalued.
Does Organigram Global pay dividends?
Organigram Global does not currently pay dividends.
What is Organigram Global’s EPS estimate?
Organigram Global’s EPS estimate is >-0.01.
How many shares outstanding does Organigram Global have?
Organigram Global has 136,337,340 shares outstanding.
What happened to Organigram Global’s price movement after its last earnings report?
Organigram Global reported an EPS of $0.103 in its last earnings report, beating expectations of -$0.007. Following the earnings report the stock price went down -12.579%.
Which hedge fund is a major shareholder of Organigram Global?
Currently, no hedge funds are holding shares in OGI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Organigram Global Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$2.66 (90.00% Upside)
$2.66 (90.00% Upside)
Blogger Sentiment
Bullish
OGI Sentiment 100%
Sector Average ―
Sector Average ―
Insider Transactions
Sold Shares
Worth $118.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.9%
Last 30 Days ▼ 1.8%
Last 30 Days ▼ 1.8%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
44.92%
12-Months-Change
Fundamentals
Return on Equity
4.86%
Trailing 12-Months
Asset Growth
16.19%
Trailing 12-Months
Company Description
Organigram Global
Organigram Holdings Inc., through its subsidiaries, produces and sells cannabis and cannabis-derived products in Canada. It offers medical cannabis products, including cannabis flowers, cannabis oils, and vaporizers for civilian patients and veterans; adult use recreational cannabis under the Edison Cannabis Co., Trail Blazer, SHRED, SHRED'ems, Big Bag O' Buds, and Monjour brands; and cannabis edibles products and concentrates. The company also engages in the wholesale shipping of cannabis plant cuttings, dried flowers, blends, pre-rolls, and cannabis derivative based products to retailers and wholesalers for adult-use recreational cannabis. It sells its products through online, as well as telephone channels. Organigram Holdings Inc. was founded in 2013 and is headquartered in Moncton, Canada.
OGI Company Deck
OGI Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed substantial operational and financial progress: strong year-over-year revenue (+49%), adjusted gross profit (+67%), adjusted EBITDA (+273%), cultivation scale gains (+43% harvested kg), and important plant-science and manufacturing advances. Management emphasized recovery from discrete disruptions (BC strike, out-of-spec international flower) and reiterated full-year guidance (> $300M revenue) and confidence in margin expansion. Key risks include a roughly $3.5M international revenue impact from out-of-spec flower (now being repurposed domestically), elevated competition in vapes/IPRs, near-term working capital-driven cash usage, pending EU GMP timing, and slow U.S. penetration. Overall, the positive financial momentum, margin improvement, operational breakthroughs and clear mitigation plans outweigh the temporary operational and market headwinds.View all OGI earnings summariesOGI Stock 12 Month Forecast
Average Price Target
$2.66
▲(90.00% Upside)
Technical Analysis
Canopy Growth
―
Aurora Cannabis
―
Cronos Group
―
Curaleaf Holdings
―
Green Thumb Industries
―
Ownership Overview
0.34% Insiders
0.05% Mutual Funds
1.46% Other Institutional Investors
94.98% Public Companies and
Individual Investors